tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

DNLI Stock Latest News

Denali Therapeutics price target lowered to $32 from $36 at Stifel
The FlyDenali Therapeutics price target lowered to $32 from $36 at Stifel
21d ago
DNLI
Denali Therapeutics price target lowered to $70 from $85 at Oppenheimer
The FlyDenali Therapeutics price target lowered to $70 from $85 at Oppenheimer
21d ago
DNLI
Denali Therapeutics price target lowered to $50 from $80 at Evercore ISI
The FlyDenali Therapeutics price target lowered to $50 from $80 at Evercore ISI
23d ago
DNLI
3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
Stock Analysis & Ideas3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
23d ago
AMZN
DNLI
Denali Therapeutics price target lowered to $38 from $46 at Wedbush
The FlyDenali Therapeutics price target lowered to $38 from $46 at Wedbush
23d ago
DNLI
Denali Therapeutics reports Q4 EPS (75c), consensus (79c)
The FlyDenali Therapeutics reports Q4 EPS (75c), consensus (79c)
24d ago
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Press ReleasesDenali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
24d ago
DNLI
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
Press ReleasesDenali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
29d ago
DNLI
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
Press ReleasesDenali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
1M ago
DNLI
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analysts to hold analyst/industry conference call
2M ago
DNLI
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analysts to hold analyst/industry conference call
2M ago
DNLI
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analysts to hold analyst/industry conference call
2M ago
DNLI
Denali Therapeutics initiated with an Outperform at SVB Securities
The FlyDenali Therapeutics initiated with an Outperform at SVB Securities
2M ago
DNLI
Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial
The FlyDenali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial
2M ago
SNY
DNLI
Centogene, Denali extend observational study on Parkinson’s disease genetics
The FlyCentogene, Denali extend observational study on Parkinson’s disease genetics
2M ago
CNTG
DNLI
Denali Therapeutics announces 2023 milestones
The FlyDenali Therapeutics announces 2023 milestones
2M ago
DNLI
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Press ReleasesDenali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
2M ago
DNLI
Denali interim P1b study results in ALS ‘positive,’ says Cantor Fitzgerald
The FlyDenali interim P1b study results in ALS ‘positive,’ says Cantor Fitzgerald
4M ago
DNLI
Denali Therapeutics initiated with an Outperform at Cowen
The FlyDenali Therapeutics initiated with an Outperform at Cowen
4M ago
DNLI
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
Press ReleasesDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
4M ago
DNLI
Denali Therapeutics announces DNL343 interim Phase 1b data in ALS
The FlyDenali Therapeutics announces DNL343 interim Phase 1b data in ALS
4M ago
DNLI
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
Press ReleasesDenali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
5M ago
DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock
Press ReleasesDenali Therapeutics Announces Proposed Offering of Common Stock
5M ago
DNLI
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Press ReleasesBiogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
6M ago
DNLI
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.